These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23420182)

  • 1. Guest editorial: basic and clinical updates in multiple myeloma.
    Kizaki M
    Int J Hematol; 2013 Mar; 97(3):304-5. PubMed ID: 23420182
    [No Abstract]   [Full Text] [Related]  

  • 2. Influencing the Wnt signaling pathway in multiple myeloma.
    Kim Y; Reifenberger G; Lu D; Endo T; Carson DA; Gast SM; Meschenmoser K; Nowak M; Schmidt-Wolf IG
    Anticancer Res; 2011 Feb; 31(2):725-30. PubMed ID: 21378363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
    Hideshima T; Anderson KC
    Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances in the study of hematopoietic cell apoptosis in multiple myeloma].
    Zhao M; Shao Z
    Zhonghua Xue Ye Xue Za Zhi; 1999 Jun; 20(6):334-6. PubMed ID: 11721392
    [No Abstract]   [Full Text] [Related]  

  • 5. When to initiate treatment in smoldering multiple myeloma.
    Mateos MV
    Clin Adv Hematol Oncol; 2017 Oct; 15(10):751-753. PubMed ID: 29040254
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
    Rajkumar SV; Buadi F
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multiple myeloma].
    Krome S
    Dtsch Med Wochenschr; 2012 Mar; 137 Suppl 1():S14-7. PubMed ID: 22438117
    [No Abstract]   [Full Text] [Related]  

  • 8. CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
    Rawstron AC; Laycock-Brown G; Hale G; Davies FE; Morgan GJ; Child JA; Hillmen P; Owen RG
    Haematologica; 2006 Nov; 91(11):1577-8. PubMed ID: 17043027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Human plasmacytoma from biology to clinical practice].
    Bataille R; Klein B
    Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):179-82. PubMed ID: 8337119
    [No Abstract]   [Full Text] [Related]  

  • 10. Case study of intracerebral plasmacytoma as an initial presentation of multiple myeloma.
    Wavre A; Baur AS; Betz M; Mühlematter D; Jotterand M; Zaman K; Ketterer N
    Neuro Oncol; 2007 Jul; 9(3):370-2. PubMed ID: 17522337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biclonal origin prevails in concomitant chronic lymphocytic leukemia and multiple myeloma.
    Pantic M; Schroettner P; Pfeifer D; Rawluk J; Denz U; Schmitt-Gräff A; Veelken H; Wäsch R; Engelhardt M
    Leukemia; 2010 Apr; 24(4):885-90. PubMed ID: 20090779
    [No Abstract]   [Full Text] [Related]  

  • 12. Defining IgM multiple myeloma.
    Owen RG; Feyler S; O'Connor SJ; Bond LR; de Tute RM; Rawstron AC
    Am J Hematol; 2011 Aug; 86(8):717; author reply 718-9. PubMed ID: 21761439
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic factors and staging in multiple myeloma.
    Fonseca R; San Miguel J
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1115-40, ix. PubMed ID: 17996591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonal heterogeneity in plasma cell myeloma.
    Quinn JG; Sadek I
    Lancet; 2016 Mar; 387(10022):e22. PubMed ID: 26456413
    [No Abstract]   [Full Text] [Related]  

  • 15. Introduction by the Guest Editor: Recent advances in biology and treatment of multiple myeloma.
    Tanaka H
    Int J Hematol; 2020 Apr; 111(4):494-495. PubMed ID: 31984452
    [No Abstract]   [Full Text] [Related]  

  • 16. Bone marrow trephine biopsy findings in myeloma with small-lymphoid cells and CCND1 translocation.
    Abdalla S; May PC; Garimberti E; Naresh KN
    Am J Hematol; 2011 Dec; 86(12):1038. PubMed ID: 21898528
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical course and phenotypic instability in 4 cases of multiple myeloma: a biological model of tumors].
    Seminara P; Franchi F; Pisanelli GC; Abdolrahimzadeh S; Aronne T; Afeltra A; Bonomo L
    Medicina (Firenze); 1989; 9(2):179-82. PubMed ID: 2811643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation.
    Xu D; Hu J; Xu S; De Bruyne E; Menu E; Van Camp B; Vanderkerken K; Van Valckenborgh E
    Leukemia; 2012 Jun; 26(6):1402-5. PubMed ID: 22094583
    [No Abstract]   [Full Text] [Related]  

  • 19. [Multiple myeloma. Biological, prognostic, and therapeutic aspects].
    Corrado C; Pavlovsky S
    Sangre (Barc); 1990 Aug; 35(4):289-97. PubMed ID: 1703328
    [No Abstract]   [Full Text] [Related]  

  • 20. [5-azacytidine treatment induces tumor suppressor gene XAF1 expression and inhibits proliferation in myeloma cells].
    Chen GH; Lin FR; Wu DP; Wang Y; Huang HW; Tang XW; Zhu ZL; Feng YF; Chang WR
    Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):229-32. PubMed ID: 19731821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.